U.S. doctors’ group endorses event-based PrEP

AMSTERDAM — For the first time, a U.S.-based doctors group has endorsed event-based PrEP use.

AIDSMap.com reported that the International Antiviral Society-USA (IAS-USA) made the recommendation during the International AIDS Conference in Amsterdam last month.

In this case, event-based means PrEP is given on demand instead of a regular daily dose. According to AIDSMap, IAS-USA recommends event-driven PrEP as an alternative for cisgender men who have sex with men, following the protocol used in the IPERGAY study: i.e. a double dose (two pills) of TDF/FTC between 24 and two hours in advance of anticipated sex, then, if sex happens, one pill the following day and one the day after – or to be continued daily until two days after the last sex.

The website reported that the group warns against event-driven dosing for women (as vaginal tissue concentrations only reach 10% of rectal concentrations), for all transgender people, and for people at risk through drug injection (for lack of evidence).

Read the full article on AIDSMap.


Know a useful resource?

Share it with your community!

We aggregate links that connect to resources across Illinois. If you know of a site that should be included or want your website listed, please submit it!


Get LGBTQ news sent right to you!

We share original stories, plus essential headlines from across the state and beyond, to keep you current on LGBTQ issues and community.


This site uses cookies to provide you with a great user experience. By continuing to use this website, you consent to the use of cookies in accordance with our privacy policy.

Scroll to Top